bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
As cases of COVID-19 are on the rise again in several places in the U.S., the need for effective treatment remains. Many potential COVID-19 treatments that could have an impact on our ability to fight the virus are currently being developed or tested in clinical trials.
In the United States, Group B Streptococcus (GBS) bacteria are a leading cause of meningitis and sepsis in a newborn’s first three months of life. The bacteria may be passed from pregnant women to their babies during delivery, because about one in every four pregnant women carry GBS bacteria in their body.
The farthest-along candidates are a viral vector vaccine being tested by the University of Oxford and AstraZeneca, a repurposed vaccine, originally developed in the early 1900s for protection against tuberculosis, and a whole-virus vaccine being tested by the state-owned Chinese company Sinopharm.
The Global Sepsis Alliance has stated that COVID-19 can cause sepsis, the body’s overwhelming and life-threatening response to an infection that can lead to organ damage and death. In the U.S., one in three patients who die in a hospital die of sepsis. Many different types of infections can cause sepsis, but the most common cause is pneumonia.
Amid the spread of COVID-19, testing for SARS-COV-2, the virus...
Patients at the greatest risk for secondary infections, particularly infections...